INmune Bio stock heads into Maxim summit before Q3 results

Published on 10/08/2026 at 01:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

INmune Bio stock carried a USD 49.4 million market cap on October 7, 2026. The Maxim summit starts October 12 before Q3 results on October 29.

INMB, US45782T1051, Illustration mit AI erstellt.

INmune Bio (ISIN US45782T1051) stock was last at USD 1.86 on October 7, 2026 at 4:00 p.m. ET, down 0.53 percent from the prior close of USD 1.87. The company is heading into a scheduled investor event that puts its clinical pipeline back on the calendar.

Maxim summit starts October 12

According to INmune Bio in a release dated October 6, 2026, the company will attend the Maxim Growth Summit from October 12 to October 14 in New York City. Chief Executive Officer David Moss is scheduled to present on an immunology and inflammation therapies panel on October 14 at 10:30 a.m.

The event gives management a near-term platform to discuss two late-stage development programs. The company says CORDStrom is moving toward regulatory filings for its Ebstrocel program, while XPro1595 is being advanced toward an adaptive Phase 2b/3 program in early Alzheimer's disease, according to the same INmune Bio release.

Small market value raises the stakes

INmune Bio's market capitalization stood at USD 49.4 million on October 7, 2026, with trading volume of 104,364 shares. The session range was USD 1.82 to USD 1.88, keeping the last price inside a narrow band around the day's high.

The 52-week range of USD 1.09 to USD 2.60 shows the stock was 28.46 percent below its yearly high on October 7. That gap matters because the company remains a clinical-stage biotechnology issuer whose valuation depends heavily on regulatory progress and future trial execution rather than established product sales.

Q3 report is the next checkpoint

MarketBeat lists October 29, 2026, as the date for INmune Bio's third-quarter report after the market closes, with a conference call scheduled for 4:30 p.m. ET. The same listing gives a consensus EPS estimate of negative USD 0.15 and expected revenue of USD 1.88 million for Q3 2026.

For investors, the October sequence separates communication from measurable results. The summit may provide updates on regulatory planning and development priorities, while the October 29 report should show whether the company's cash position and operating spending have changed since the second quarter.

INmune Bio stock stays below yearly high

INmune Bio stock was last at USD 1.86 on Nasdaq on October 7, 2026 at 4:00 p.m. ET. The company reported a 52-week high of USD 2.60 and a 52-week low of USD 1.09, leaving regulatory milestones and the Q3 report as the next dated checkpoints for the shares.